New concepts and best practices for management of pre- and post-transplantation cancer

Transplantation Reviews

Volumn 26, Issue 4, 2012, Pages 261-279

  Campistol, Josep M ^a   Cuervas Mons, Valentín ^b   Manito, Nicolás ^c   Almenar, Luis ^d   Arias, Manuel ^e   Casafont, Fernando ^e   del Castillo, Domingo ^f   Crespo Leiro, María G ^g   Delgado, Juan F ^h   Herrero, J Ignacio ⁱ   Jara, Paloma ^j   Morales, José M ^h   Navarro, Mercedes ^j   Oppenheimer, Federico ^a   Prieto, Martín ^d   Pulpón, Luis A ^b   Rimola, Antoni ^a   Román, Antonio ^k   Serón, Daniel ^k   Ussetti, Piedad ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g UNIVERSITY OF A CORUÑA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ UNIVERSITY CLINIC OF NAVARRA   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN P53; RAPAMYCIN; RETINOBLASTOMA PROTEIN; RITUXIMAB; VASCULOTROPIN;

APOPTOSIS; BREAST CANCER; BRONCHOALVEOLAR CELL CARCINOMA; CANCER PREVENTION; CANCER RECURRENCE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHORIOCARCINOMA; COLON CANCER; DONOR; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFECTION PREVENTION; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LATENT PERIOD; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MALIGNANT TRANSFORMATION; MEDICAL HISTORY; MELANOMA; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NON MELANOMA SKIN CANCER; ONCOVIRINAE; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION CANCER; PRETRANSPLANTATION CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SCREENING; SUN EXPOSURE; TUMOR ESCAPE; TUMOR VASCULARIZATION; UROGENITAL TRACT CANCER; VIRUS CARCINOGENESIS; VIRUS INFECTION;

EID: 84866746454     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2012.07.001     Document Type: Review

References (202)

1. Hariharan S., Johnson C.P., Bresnahan B.A., Taranto S.E., McIntosh M.J., Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342:605-612.
2. Lanza L.L., Wang L., Simon T.A., Irish W.D. Epidemiologic critique of literature on post-transplant neoplasms in solid organ transplantation. Clin Transplant 2009, 23:582-588.
3. Lodhi S.A., Lamb K.E., Meier-Kriesche H.U. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011, 11:1226-1235.
4. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383.
5. Lamb K.E., Lodhi S., Meier-Kriesche H.U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011, 11:450-462.
6. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
7. Kellerman L., Neugut A., Burke B., Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol 2009, 103:562-566.
8. Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004, 4:905-913.
9. Aberg F., Pukkala E., Hockerstedt K., Sankila R., Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008, 14:1428-1436.
10. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998, 147-158.
11. Adami J., Gabel H., Lindelof B., et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003, 89:1221-1227.
12. Amital A., Shitrit D., Raviv Y., et al. Development of malignancy following lung transplantation. Transplantation 2006, 81:547-551.
13. Engels E.A., Pfeiffer R.M., Fraumeni J.F., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306:1891-1901.
14. Collett D., Mumford L., Banner N.R., Neuberger J., Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010, 10:1889-1896.
15. Herrero J.I., Lorenzo M., Quiroga J., et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005, 11:89-97.
16. Herrero J.I. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009, 15(Suppl. 2):S90-S94.
17. Jiang Y., Villeneuve P.J., Wielgosz A., Schaubel D.E., Fenton S.S., Mao Y. The incidence of cancer in a population-based cohort of Canadian heart transplant recipients. Am J Transplant 2010, 10:637-645.
18. Crespo-Leiro M.G., Alonso-Pulpon L., Vazquez de Prada J.A., et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant 2008, 8:1031-1039.
19. Crespo-Leiro M.G., Villa-Arranz A., Manito-Lorite N., et al. Lung cancer after heart transplantation: results from a large multicenter registry. Am J Transplant 2011, 11:1035-1040.
20. Crespo-Leiro M.G., Alonso-Pulpon L.A., Villa-Arranz A., et al. The prognosis of noncutaneous, nonlymphomatous malignancy after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. Transplant Proc 2010, 42:3011-3013.
21. Baccarani U., Adani G.L., Montanaro D., et al. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc 2006, 38:1135-1137.
22. Robbins H.Y., Arcasoy S.M. Malignancies following lung transplantation. Clin Chest Med 2011, 32:343-355.
23. Wimmer C.D., Rentsch M., Crispin A., et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007, 71:1271-1278.
24. Danpanich E., Kasiske B.L. Risk factors for cancer in renal transplant recipients. Transplantation 1999, 68:1859-1864.
25. Opelz G., Dohler B. Impact of HLA mismatching on incidence of post-transplant non-hodgkin lymphoma after kidney transplantation. Transplantation 2010, 89:567-572.
26. Chak E., Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010, 30:1247-1258.
27. Herrero J.I., Pardo F., D'Avola D., et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl 2011, 17:402-408.
28. Benlloch S., Berenguer M., Prieto M., et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?. Am J Transplant 2004, 4:596-604.
29. Tjon A.S., Sint Nicolaas J., Kwekkeboom J., et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010, 16:837-846.
30. Metcalfe M.J., Kutsogiannis D.J., Jackson K., et al. Risk factors and outcomes for the development of malignancy in lung and heart-lung transplant recipients. Can Respir J 2010, 17:e7-e13.
31. Agraharkar M.L., Cinclair R.D., Kuo Y.F., Daller J.A., Shahinian V.B. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004, 66:383-389.
32. Moloney F.J., Comber H., O'Lorcain P., O'Kelly P., Conlon P.J., Murphy G.M. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006, 154:498-504.
33. Feng S., Buell J.F., Cherikh W.S., et al. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation 2002, 74:1657-1663.
34. Campistol J., Morales J. Manejo de tumores tras el trasplante renal. Nefrologia 2009, 29:33-45.
35. Vegso G., Toth M., Hidvegi M., et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res 2007, 13:63-69.
36. ISHLT The registry of the international society for heart and lung transplantation - 2010. J Heart Lung Transplant 2010, 29:1083-1141.
37. Buell J.F., Gross T.G., Woodle E.S. Malignancy after transplantation. Transplantation 2005, 80:S254-S264.
38. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
39. Rama I., Grinyo J.M. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 2010, 6:511-519.
40. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
41. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
42. Gutierrez-Dalmau A., Campistol J.M. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67:1167-1198.
43. Dantal J., Hourmant M., Cantarovich D., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628.
44. Soulillou J.P., Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001, 72:S89-S93.
45. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
46. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
47. Bhatia A., Kumar Y. Cancer-immune equilibrium: questions unanswered. Cancer Microenviron 2011, 4:209-217.
48. Strauss D.C., Thomas J.M. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010, 11:790-796.
49. Teng M.W., Swann J.B., Koebel C.M., Schreiber R.D., Smyth M.J. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008, 84:988-993.
50. Pagano J.S., Blaser M., Buendia M.A., et al. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 2004, 14:453-471.
51. Butel J.S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000, 21:405-426.
52. Saha A., Kaul R., Murakami M., Robertson E.S. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol Ther 2010, 10:961-978.
53. Kotton C.N., Fishman J.A. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005, 16:1758-1774.
54. Tanner J.E., Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001, 3:60-69.
55. Datta D., Contreras A.G., Basu A., et al. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res 2009, 69:8902-8909.
56. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
57. Herman M., Weinstein T., Korzets A., et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001, 137:14-20.
58. Yarosh D.B., Pena A.V., Nay S.L., Canning M.T., Brown D.A. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005, 125:1020-1025.
59. Maluccio M., Sharma V., Lagman M., et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003, 76:597-602.
60. Koehl G.E., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004, 77:1319-1326.
61. Alberu J., Pascoe M.D., Campistol J.M., et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011, 92:303-310.
62. Koehl G.E., Wagner F., Stoeltzing O., et al. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 2007, 83:607-614.
63. Kauffman H.M., Cherikh W.S., McBride M.A., Cheng Y., Hanto D.W. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 2007, 84:272-274.
64. Ison M.G., Nalesnik M.A. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011, 11:1123-1130.
65. Ison M.G., Hager J., Blumberg E., et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009, 9:1929-1935.
66. Garrido G., Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. Transplantation 2008, 85:S61-S63.
67. Kauffman H.M., McBride M.A., Delmonico F.L. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000, 70:1747-1751.
68. Birkeland S.A., Storm H.H. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002, 74:1409-1413.
69. Organización Nacional de Trasplantes registry report - 2011. Available at: Last access: May 2012. http://www.ont.es/infesp/Paginas/DatosdeDonacionyTrasplante.aspx.
70. Buell J.F., Beebe T.M., Trofe J., et al. Donor transmitted malignancies. Ann Transplant 2004, 9:53-56.
71. Myron Kauffman H., McBride M.A., Cherikh W.S., Spain P.C., Marks W.H., Roza A.M. Transplant tumor registry: donor related malignancies. Transplantation 2002, 74:358-362.
72. Feng S., Buell J.F., Chari R.S., DiMaio J.M., Hanto D.W. Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003, 3:1481-1487.
73. Buell J.F., Hanaway M.J., Thomas M., et al. Donor kidneys with small renal cell cancers: can they be transplanted?. Transplant Proc 2005, 37:581-582.
74. Whitson J.M., Stackhouse G.B., Freise C.E., Meng M.V., Stoller M.L. Laparoscopic nephrectomy, ex vivo partial nephrectomy followed by allograft renal transplantation. Urology 2007, 70(1007):e1001-e1003.
75. Kauffman H.M., McBride M.A., Cherikh W.S., Spain P.C., Delmonico F.L. Transplant tumor registry: donors with central nervous system tumors1. Transplantation 2002, 73:579-582.
76. Chui A.K., Herbertt K., Wang L.S., et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc 1999, 31:1266-1267.
77. Section II. Evaluation and selection of donors. Nephrol Dial Transplant 2000, 15(Suppl 7):39-51. EBPG (European Expert Group on Renal Transplantation); European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1).
78. Penn I. Transmission of cancer from organ donors. Nefrología XV 1995, 205-213.
79. Buell J.F., Alloway R.R., Steve Woodle E. How can donors with a previous malignancy be evaluated?. J Hepatol 2006, 45:503-507.
80. Selected recommendations of the OPTN/UNOS living donor committee to the board of directors. Available at Last access: May 2012. http://www.unos.org.
81. Nalesnik M.A., Woodle E.S., Dimaio J.M., et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 2011, 11:1140-1147.
82. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 2002, 17(Suppl 4):32-36. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6. Cancer risk after renal transplantation. IV.6.3.
83. Kasiske B.L., Cangro C.B., Hariharan S., et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001, 1(Suppl. 2):3-95.
84. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
85. Benten D., Sterneck M., Panse J., Rogiers X., Lohse A.W. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 2008, 14:789-798.
86. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993, 55:742-747.
87. Uberfuhr P., Meiser B., Fuchs A., et al. Heart transplantation: an approach to treating primary cardiac sarcoma?. J Heart Lung Transplant 2002, 21:1135-1139.
88. Vegso G., Gorog D., Fehervari I., et al. Role of organ transplantation in the treatment of malignancies - hepatocellular carcinoma as the most common tumour treated with transplantation. Pathol Oncol Res 2012, 18:1-10.
89. Sotiropoulos G.C., Druhe N., Sgourakis G., et al. Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?. Dig Dis Sci 2009, 54:2264-2273.
90. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
91. Center M.M., Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011, 20:2362-2368.
92. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991, 214:221-228. [discussion 228-229].
93. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
94. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
95. Befeler A.S., Hayashi P.H., Di Bisceglie A.M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005, 128:1752-1764.
96. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
97. Onaca N., Davis G.L., Goldstein R.M., Jennings L.W., Klintmalm G.B. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007, 13:391-399.
98. Kneteman N.M., Oberholzer J., Al Saghier M., et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004, 10:1301-1311.
99. Roayaie S., Frischer J.S., Emre S.H., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002, 235:533-539.
100. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007, 246:502-509. [discussion 509-511].
101. Leung J.Y., Zhu A.X., Gordon F.D., et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004, 10:1343-1354.
102. Decaens T., Roudot-Thoraval F., Hadni-Bresson S., et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006, 12:1761-1769.
103. Vitale A., Morales R.R., Zanus G., et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011, 12:654-662.
104. Majno P.E., Adam R., Bismuth H., et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997, 226:688-701. [discussion 701-683].
105. Gordon-Weeks A.N., Snaith A., Petrinic T., Friend P.J., Burls A., Silva M.A. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011, 98:1201-1208.
106. Bargellini I., Vignali C., Cioni R., et al. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria - selection parameter for liver transplantation. Radiology 2010, 255:289-300.
107. Orens J.B., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25:745-755.
108. de Perrot M., Chernenko S., Waddell T.K., et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease. J Clin Oncol 2004, 22:4351-4356.
109. Verleden G.M., Fisher A.J. Lung transplantation and lung cancer: is there a link?. Respiration 2011, 81:441-445.
110. Laskin J.J. Bronchoalveolar carcinoma: current treatment and future trends. Clin Lung Cancer 2004, 6(Suppl. 2):S75-S79.
111. Breathnach O.S., Kwiatkowski D.J., Finkelstein D.M., et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg 2001, 121:42-47.
112. Garver R.I., Zorn G.L., Wu X., McGiffin D.C., Young K.R., Pinkard N.B. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999, 340:1071-1074.
113. Paloyan E.B., Swinnen L.J., Montoya A., Lonchyna V., Sullivan H.J., Garrity E. Lung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs. Transplantation 2000, 69:2446-2448.
114. Roithmaier S., Haydon A.M., Loi S., et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007, 26:845-849.
115. Stehlik J., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report - 2010. J Heart Lung Transplant 2010, 29:1089-1103.
116. Almenar L., Segovia J., Crespo-Leiro M.G., et al. Spanish Heart Transplantation Registry. 21st official report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2009). Rev Esp Cardiol 2010, 63:1317-1328.
117. Girndt M., Kohler H. Waiting time for patients with history of malignant disease before listing for organ transplantation. Transplantation 2005, 80:S167-S170.
118. EBPG (European Group on Renal Transplantation); European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1). Section I: Evaluation, selection and preparation of the potential transplant recipient. I.5. Risk factors/relative contra-indications. Nephrol Dial Transplant 2000, 15(Suppl. 7):6-25.
119. Castroagudin J.F., Molina E., Bustamante M., et al. Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience. Transplant Proc 2008, 40:2975-2977.
120. Toso C., Mentha G., Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011, 11:2031-2035.
121. Zhou J., Wang Z., Wu Z.Q., et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008, 40:3548-3553.
122. Vivarelli M., Dazzi A., Zanello M., et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010, 89:227-231.
123. Chinnakotla S., Davis G.L., Vasani S., et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009, 15:1834-1842.
124. Schnitzbauer A.A., Zuelke C., Graeb C., et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010, 10:190.
125. Gomez-Martin C., Bustamante J., Castroagudin J.F., et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012, 18:45-52.
126. Toso C., Asthana S., Bigam D.L., Shapiro A.M., Kneteman N.M. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009, 49:832-838.
127. Xu J., Shen Z.Y., Chen X.G., et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007, 45:269-276.
128. Toso C., Merani S., Bigam D.L., Shapiro A.M., Kneteman N.M. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51:1237-1243.
129. Opelz G., Dohler B. Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report. Am J Transplant 2011, 11:2483-2489.
130. Dantal J., Soulillou J.P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005, 352:1371-1373.
131. Molina B.D., Leiro M.G., Pulpon L.A., et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transplant Proc 2010, 42:3001-3005.
132. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
133. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006, 17:581-589.
134. Shroff R., Rees L. The post-transplant lymphoproliferative disorder - a literature review. Pediatr Nephrol 2004, 19:369-377.
135. Dierickx D., Tousseyn T., De Wolf-Peeters C., Pirenne J., Verhoef G. Management of post-transplant lymphoproliferative disorders following solid organ transplant: an update. Leuk Lymphoma 2011, 52:950-961.
136. Torpey N. Renal transplantation 2010, Oxford Specialist Handbooks, Oxford, England.
137. Winkelhorst J.T., Brokelman W.J., Tiggeler R.G., Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001, 27:409-413.
138. Jain A.B., Yee L.D., Nalesnik M.A., et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998, 66:1193-1200.
139. Angel L.F., Cai T.H., Sako E.Y., Levine S.M. Post-transplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000, 5:26-30.
140. Libertiny G., Watson C.J., Gray D.W., Welsh K.I., Morris P.J. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001, 88:1330-1334.
141. Opelz G., Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993, 342:1514-1516.
142. Jamil B., Nicholls K., Becker G.J., Walker R.G. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999, 68:1597-1603.
143. Durrbach A., Pestana J.M., Pearson T., et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10:547-557.
144. Vincenti F., Charpentier B., Vanrenterghem Y., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
145. Vincenti F., Larsen C.P., Alberu J., et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012, 12:210-217.
146. Berber I., Altaca G., Aydin C., et al. Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis. Transplant Proc 2005, 37:967-968.
147. Euvrard S., Kanitakis J. Skin cancers after liver transplantation: what to do?. J Hepatol 2006, 44:27-32.
148. Regamey N., Tamm M., Wernli M., et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998, 339:1358-1363.
149. Cattani P., Capuano M., Graffeo R., et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol 2001, 39:506-508.
150. Emond J.P., Marcelin A.G., Dorent R., et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol 2002, 40:2217-2219.
151. Marcelin A.G., Roque-Afonso A.M., Hurtova M., et al. Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 2004, 10:295-300.
152. Cai Q., Verma S.C., Lu J., Robertson E.S. Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res 2010, 78:87-142.
153. Einollahi B. Kaposi sarcoma after kidney transplantation. Iran J Kidney Dis 2007, 1:2-11.
154. Volkow P., Zinser J.W., Correa-Rotter R. Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC Nephrol 2007, 8:6.
155. Nichols L.A., Adang L.A., Kedes D.H. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One 2011, 6:e14535.
156. Lebbe C., Legendre C., Frances C. Kaposi sarcoma in transplantation. Transplant Rev (Orlando) 2008, 22:252-261.
157. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005, 352:1317-1323.
158. Bouwes Bavinck J.N., Berkhout R.J. HPV infections and immunosuppression. Clin Dermatol 1997, 15:427-437.
159. Rudlinger R., Smith I.W., Bunney M.H., Hunter J.A. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986, 115:681-692.
160. Klatte T., Seitz C., Waldert M., et al. Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. BJU Int 2010, 105:1260-1265.
161. Tsivian M, Caso JR, Kimura M, Polascik TJ. Renal tumors in solid organ recipients: Clinical and pathologic features. Urol Oncol. (in press).
162. Vegso G., Toronyi E., Hajdu M., et al. Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant Proc 2011, 43:1261-1263.
163. Crespo-Leiro M.G., Alonso-Pulpon L., Arizon J.M., et al. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. J Heart Lung Transplant 2007, 26:1105-1109.
164. KDIGO KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S155.
165. USPSTF Screening for skin cancer: U.S. preventive service task force recommendation statement. Ann Intern Med 2009, 188-193.
166. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000, 11(Suppl. 15):S1-S86.
167. Kerkar N., Morotti R.A., Madan R.P., et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant 2010, 14:504-511.
168. Mandelblatt J.S., Lawrence W.F., Gaffikin L., et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002, 94:1469-1483.
169. Mandelblatt J.S., Cronin K.A., Bailey S., et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009, 151:738-747.
170. Lim L.S., Sherin K. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med 2008, 34:164-170.
171. Rex D.K., Johnson D.A., Anderson J.C., Schoenfeld P.S., Burke C.A., Inadomi J.M. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009, 104:739-750.
172. Calonge N., Petitti D.B., DeWitt T.G., et al. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:627-637. on behalf of the U.S. Preventive Services Task Force.
173. Aberle D.R., Adams A.M., Berg C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
174. Finkenstedt A., Graziadei I.W., Oberaigner W., et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009, 9:2355-2361.
175. Herrero J.I., Alegre F., Quiroga J., et al. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant 2009, 23:532-536.
176. Opelz G., Daniel V., Naujokat C., Fickenscher H., Dohler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007, 8:212-218.
177. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990, 323:1723-1728.
178. Bakker N.A., van Imhoff G.W., Verschuuren E.A., van Son W.J. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 2007, 20:207-218.
179. Geissler E.K., Schlitt H.J., Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008, 8:2212-2218.
180. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
181. Zuckermann A., Manito N., Epailly E., et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008, 27:141-149.
182. Kahan B.D., Yakupoglu Y.K., Schoenberg L., et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005, 80:749-758.
183. Rostaing L., Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. J Nephrol 2010, 23:133-142.
184. Sharif A., Shabir S., Chand S., Cockwell P., Ball S., Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011, 22:2107-2118.
185. Campistol J.M. Minimizing the risk of post-transplant malignancy. Transplantation 2009, 87:S19-S22.
186. Epailly E., Albanell J., Andreassen A., et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. Clin Transplant 2011, 25:E475-E486.
187. Foster B.J., Dahhou M., Zhang X., Platt R.W., Hanley J.A. Change in mortality risk over time in young kidney transplant recipients. Am J Transplant 2011, 11:2432-2442.
188. Debray D., Baudouin V., Lacaille F., et al. De novo malignancy after solid organ transplantation in children. Transplant Proc 2009, 41:674-675.
189. Buell J.F., Gross T.G., Thomas M.J., et al. Malignancy in pediatric transplant recipients. Semin Pediatr Surg 2006, 15:179-187.
190. Ng V.L., Fecteau A., Shepherd R., et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a north american multicenter registry. Pediatrics 2008, 122:e1128-e1135.
191. Dharnidharka V.R., Sullivan E.K., Stablein D.M., Tejani A.H., Harmon W.E. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001, 71:1065-1068.
192. Gao S.Z., Chaparro S.V., Perlroth M., et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003, 22:505-514.
193. Lee T.C., Savoldo B., Barshes N.R., et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 2006, 20:389-393.
194. Reyes J., Bueno J., Kocoshis S., et al. Current status of intestinal transplantation in children. J Pediatr Surg 1998, 33:243-254.
195. Faye A., Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs 2005, 7:55-65.
196. Parker A., Bowles K., Bradley J.A., et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS guidelines. Br J Haematol 2010, 149:693-705.
197. Post-transplant lymphoproliferative disorder section integrated into updated NCCN guidelines for NHL. J Natl Compr Canc Netw 2011, 9:xxxiii-xli.
198. Madan R.P., Herold B.C. Viral infections in pediatric solid organ transplantation recipients and the impact of molecular diagnostic testing. Curr Opin Organ Transplant 2010, 15:293-300.
199. Boyle G.J., Michaels M.G., Webber S.A., et al. Post-transplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997, 131:309-313.
200. Reshef R., Vardhanabhuti S., Luskin M.R., et al. Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder (bigstar). Am J Transplant 2011, 11:336-347.
201. Hanto D.W., Frizzera G., Gajl-Peczalska K.J., et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982, 306:913-918.
202. Evens A.M., David K.A., Helenowski I., et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010, 28:1038-1046.